×
RAPS Learning Portal will be under maintenance on 24 July 2026 between 10 PM - 12 AM ET. Learning Portal functionality and profile access may be unavailable during this window.
We apologize for any inconvenience caused during this time.

rf-fullcolor.png

 

21 May 2012
by RAPS

Pfizer Recalls 653,000 Bottles of Advil After CGMP Deficiencies Cause 'Strong Odor'

New York-based pharmaceutical manufacturer Pfizer has recalled more than 653,000 bottles of its Advil Liqui-Gels pain-reliever after becoming aware of a "strong odor" in the product, reports Dow Jones Business Wire.

The products, composed of eight lots manufactured at an Argentina-based facility operated by contract manufacturing organization (CMO) Catalent Argentina S.A.I.C., were recalled from retail-distribution centers in March, according to a US Food and Drug Administration (FDA) enforcement report released 16 May 2012.

The products reportedly did not meet current good manufacturing practice specifications after being exposed to enzymatic hydrolysis for an incorrect amount of time, which in turn "caused a stronger odor" in the product, wrote FDA.

In a statement to the Dow Jones Newswire, Pfizer spokeswoman Jenifer Antonacci said the lots had been recalled and the issue isolated and corrected.


Read more:

Dow Jones Newswire - Pfizer Recalls More Than 650,000 Bottles Of Advil Liqui-Gels

FDA Enforcement Report - Advil Liqui-Gels 200 mg (ibuprofen), 40 count, 40+20 count and 240 count bottles. Recall # D-1337-2012